Anika Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio125.13
Forward P/E39.1962.00
P/S Ratio2.012.753.803.504.93
P/B Ratio1.561.561.511.802.36
Price/Tangible Book1.671.642.122.633.72
Price/FCF158.9656.25
Price/OCF44.6298.0861.6049.24
PEG Ratio161.403.10
Enterprise Value Ratios
EV/Revenue1.722.403.303.034.34
EV/EBITDA56.8818.3720.70194.38151.74
EV/EBIT182.42102.39
EV/FCF137.5149.55
Profitability & Returns
Return on Equity (ROE)-0.05%-0.01%0.01%0.01%-0.09%
Return on Assets (ROA)-0.01%0.00%0.01%-0.02%-0.02%
Return on Invested Capital (ROIC)-0.03%-0.01%0.01%-0.06%-0.06%
Return on Capital Employed (ROCE)-0.03%0.01%0.01%-0.04%-0.03%
Leverage & Solvency Ratios
Debt/Equity0.170.130.110.070.08
Debt/EBITDA3.481.421.444.123.52
Debt/FCF6.441.96
Liquidity Ratios
Current Ratio4.885.266.075.664.81
Quick Ratio3.403.064.334.173.32
Efficiency Ratios
Asset Turnover0.510.390.330.410.38
Inventory Turnover1.791.171.071.421.80
Yield & Distribution Ratios
Earnings Yield-0.23%-0.25%-0.03%0.01%-0.04%
FCF Yield-0.01%-0.02%-0.01%0.01%0.02%
Buyback Yield0.00%-0.01%0.01%-0.03%0.01%